Cargando…

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy

Detalles Bibliográficos
Autores principales:	Sato, T, Nishimura, K, Nozawa, T, Kanetaka, T, Kikuchi, M, Hara, R, Sakurai, N, Yamazaki, K, Takeuchi, Y, Yokota, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044449/ http://dx.doi.org/10.1186/1546-0096-11-S2-P122

Ejemplares similares

PReS-FINAL-2189: Tocillizumab for patients with takayasu arteritis in childhood refractory to conventional therapy
por: Yamazaki, K, et al.
Publicado: (2013)

PReS-FINAL-2172: Efficacy of corticosteroids and intravenous cyclophosphamide for patients with juvenile systemic sclerosis
por: Kikuchi, M, et al.
Publicado: (2013)

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
por: Yokota, S, et al.
Publicado: (2013)

PReS-FINAL-2041: Macrophage activation syndrome in the children with systemic juvenile idiopathic arthritis during the course of tocilizumab
por: Alekseeva, E, et al.
Publicado: (2013)

Characterization of the LysP2110-HolP2110 Lysis System in Ralstonia solanacearum Phage P2110
por: Chen, Kaihong, et al.
Publicado: (2023)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Natural autoimmunity in oligoarticular juvenile idiopathic arthritis
por: Tsitsami, Elena, et al.
Publicado: (2023)

PReS-FINAL-1018: Can the CD4/CD8β ratio be used as a predictive biomarker in extended-to-be oligoarticular JIA?
por: De Leeuw, S, et al.
Publicado: (2013)

PReS-FINAL-1004: Can the cd4/cd8β ratio be used as a predictive biomarker in extended-to-be oligoarticular JIA?
por: de Leeuw, S, et al.
Publicado: (2013)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

Oligoarticular juvenile idiopathic arthritis among Saudi children
por: Moued, Mohammed Mustafa, et al.
Publicado: (2013)

30 Oligoarticular juvenile idiopathic arthritis-associated uveitis
por: Guedri, Rahma
Publicado: (2022)

33 Oligoarticular juvenile idiopathic arthritis-associated uveitis
por: Dghaies, C, et al.
Publicado: (2022)

2110. Treatment of Coccidioidomycosis with Isavuconazole
por: Jamros, Christina, et al.
Publicado: (2019)

PReS-FINAL-2131: Hunting for biomarkers in juvenile dermatomyositis
por: Bellutti Enders, F, et al.
Publicado: (2013)

PReS-FINAL-2198: Insufficient efficacy of tocilizumab therapy in children with Castleman's disease
por: Kozlova, A, et al.
Publicado: (2013)

RE: Oligoarticular juvenile idiopathic arthritis among Saudi children
por: Al-Mendalawi, Mahmood D.
Publicado: (2014)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Children with oligoarticular juvenile idiopathic arthritis have skewed synovial monocyte polarization pattern with functional impairment—a distinct inflammatory pattern for oligoarticular juvenile arthritis
por: Schmidt, Tobias, et al.
Publicado: (2020)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013)

PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
por: Mihailova, D, et al.
Publicado: (2013)

PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
por: Rossetto, E, et al.
Publicado: (2013)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

Th17 and Th1 Lymphocytes in Oligoarticular Juvenile Idiopathic Arthritis
por: Maggi, Laura, et al.
Publicado: (2019)

PReS-FINAL-2130-A: Effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis - a national cohort study UK and Ireland
por: Moraitis, E, et al.
Publicado: (2013)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2097: Evaluation of gait in children with juvenile idiopathic arthritis
por: Baydogan, SN, et al.
Publicado: (2013)

PReS-FINAL-2008: Juvenile dermatomyositis: a report of 22 cases
por: Souto, A, et al.
Publicado: (2013)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

PReS-FINAL-2024: Responsiveness of the juvenile arthritis foot disability index
por: Esbjörnsson, AC, et al.
Publicado: (2013)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

Intra-articular corticosteroid therapy in oligoarticular juvenile arthritis: our clinical experience
por: Trigilia, C, et al.
Publicado: (2011)

PReS-FINAL-2150: Antiocular antibodies in children with juvenile idiopathic arthritis-associated uveitis
por: Walscheid, K, et al.
Publicado: (2013)

PReS-FINAL-2010: Predictive value of whole-body MRI in juvenile dermatomyositis
por: Malattia, C, et al.
Publicado: (2013)

PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis
por: Pastore, S, et al.
Publicado: (2013)

PReS-FINAL-2081: Accelerometer-assessed daily activity in juvenile idiopathic arthritis
por: Noergaard, M, et al.
Publicado: (2013)

PReS-FINAL-2109: Genetic variations in patients with juvenile idiopathic arthritis and uveitis
por: Reinards, TH, et al.
Publicado: (2013)

PReS-FINAL-2018: The P53 gene polymorphisms and juvenile idiopathic arthritis
por: Kozhevnikov, A, et al.
Publicado: (2013)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0jf576p6lu3tairan8mr0i6l06